Treatment of polyarteritis nodosa and microscopic polyangiitis

Guillevin, Loı̈c; Lhote, F.

doi:10.1002/1529-0131(199812)41:12<2100::aid-art3>3.0.co;2-j

Cited by 75 publications

(14 citation statements)

References 35 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A glomerulonefrite necrotizante é muito comum (79%-90%), e a capilarite pulmonar ocorre freqüentemente (25%-50%), com hemorragias em 12% a 29% dos doentes. 12,13 Na poliangeíte microscópica ocorrem sintomas sistêmicos como febre, mialgia, perda de peso e artralgia. A púrpura palpável manifesta-se em 46% dos pacientes na época da apresentação da doença, e cerca de 90%dos doentes têm Anca positivo no soro.…”

Section: Poliangeíte Microscópicaunclassified

Vasculites dos médios e grandes vasos

Brandt

Arnone

Valente

et al. 2009

An. Bras. Dermatol.

View full text Add to dashboard Cite

Resumo:As vasculites são constituídas por um grande grupo de síndromes caracterizadas por inflamação e necrose da parede dos vasos sangüíneos, resultando em estreitamento ou oclusão do lúmen. A distribuição dos vasos envolvidos varia consideravelmente e serve de base para a classificação das síndromes vasculíticas: grandes vasos (arterite de Takayasu, arterite temporal); pequenos e médios vasos (poliarterite nodosa, síndrome de Churg-Strauss, granulomatose de Wegener, vasculites nas doenças reumáticas); e pequenos vasos (vasculite de hipersensibilidade, púrpura de Henoch-Schonlein, poliangeíte microscópica, crioglobulinemia). Este artigo revisa as vasculites dos médios e grandes vasos e opções terapêuticas atuais; além de oferecer orientação sobre abordagem diagnóstica e tratamento dos pacientes com suspeita de vasculite cutânea. Palavras-chave: Anticorpos anticitoplasma de neutrófilos; Arterite de células gigantes; Arterite de Takayasu; Doenças reumáticas; Granulomatose de Wegener; Poliarterite nodosa; Púrpura; Síndrome de Churg-Strauss; Vasculite; Vasculite alérgica cutânea Abstract: Vasculitis comprises a broad group of syndromes characterized by inflammation and necrosis on the walls of blood vessels, resulting in narrowing or occlusion of the lumen. The distribution of involved blood vessel varies considerably and serves as the basis for one classification of vasculitic syndromes: large vessels (Takayasu arteritis, giant cell arteritis); medium and small muscular arteries (polyarteritis nodosa, Churg-Strauss syndrome, Wegener's granulomatosis, vasculitis in rheumatic diseases); and small vessels ("hypersensitivity" vasculitis, Henoch-Schonlein purpura, microscopic polyangiitis, cryoglobulinemia). This article reviews medium and large vessel vasculitis and current treatment options; it also presents a comprehensive approach to diagnosing and treating patients with suspected cutaneous vasculitis.

show abstract

Section: Poliangeíte Microscópicaunclassified

Vasculites dos médios e grandes vasos

Brandt

Arnone

Valente

et al. 2009

An. Bras. Dermatol.

View full text Add to dashboard Cite

show abstract

“…Except for these two indications, data from observational studies suggest that immunosuppressive therapy with corticosteroids or cytotoxic agents and plasmapheresis are of little benefit and are potentially harmful. This is particularly true among children with membranous nephropathy in whom spontaneous recovery over 6 to 24 months is common . The addition of cyclophosphamide to glucocorticoids and plasma exchange does not appear to improve long‐term outcomes in HBV‐associated PAN, although initial disease control may be better.…”

Section: Renal Disease Associated With Hepatitis Bmentioning

confidence: 99%

“…This is particularly true among children with membranous nephropathy in whom spontaneous recovery over 6 to 24 months is common. 21 The addition of cyclophosphamide to glucocorticoids and plasma exchange does not appear to improve long-term outcomes in HBVassociated PAN, although initial disease control may be better. There are no data on the role of other immunosuppressive agents, including mycophenolate mofetil and rituximab, in the treatment of HBV-associated PAN.…”

Section: Limited Role For Immunosuppression and Plasmapheresis-mentioning

confidence: 99%

Spectrum of hepatitis B and renal involvement

Shah

Amarapurkar

2017

Liver International

View full text Add to dashboard Cite

show abstract

“…The duration of treatment with glucocorticoid and/or immunosuppressants should not generally exceed 2 years (Class IIb, Level C). 137 Treatment with CY should be limited to 3 to 6 months. Following the induction of remission, CY should be switched to azathioprine, an agent with a lower incidence of ADRs, which should be administered for 6 to 12 months (Class IIb, Level C).…”

Section: Jcs Guidelines For Management Of Vasculitis Syndromementioning

confidence: 99%